ClinicalTrials.Veeva

Menu
P

Prolato Clinical Research Center | Houston, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Atrasentan
Obinutuzumab
GFB-887
SAR441344
Secukinumab
Ianalumab
VX-147
Semaglutide
HZN-1116
RO7434656

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

27 of 43 total trials

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

The purpose of this study is to evaluate efficacy, safety and tolerability of s.c. ianalumab administered in participants with diffuse cutaneous syst...

Enrolling
Diffuse Cutaneous Systemic Sclerosis
Drug: Ianalumab
Drug: Placebo

The purpose of this study is to measure the efficacy and safety of HZN-1116 in participants with Sjogren's syndrome (SS).

Enrolling
Sjogren's Syndrome
Drug: HZN-1116
Drug: Placebo

The purpose of this study is to measure the long-term safety and tolerability of ianalumab in participants with Sjogrens syndrome who have previously...

Enrolling
Sjogrens Syndrome
Drug: Ianalumab (VAY736)
Other: Placebo

We are doing this study to learn more about how semaglutide may help fight chronic kidney disease in people with type 2 diabetes. We are doing this b...

Active, not recruiting
Chronic Kidney Disease
Diabetes Mellitus, Type 2
Drug: Placebo (Semaglutide)
Drug: Semaglutide

The purpose of this study is to evaluate the long-term safety and tolerability, of open label iptacopan in primary IgA nephropathy participants who h...

Enrolling
Primary IgA Nephropathy
Drug: LNP023

This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of obinutuzumab compared with tacrolimus in participants w...

Active, not recruiting
Primary Membranous Nephropathy
Drug: Tacrolimus
Drug: Methylprednisolone

The purpose of this study is to determine the safety and tolerability of imvotamab in patients with severe systemic lupus erythematosus who have fail...

Enrolling
Systemic Lupus Erythematosus
Lupus Erythematosus
Drug: Imvotamab

The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and...

Enrolling
Multiple Sclerosis
Drug: LY3541860
Drug: Placebo

This study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE).

Enrolling
Systemic Lupus Erythematosus
Drug: Placebo
Drug: Obexelimab

The goal of the Phase 3a part of this clinical trial is to determine the optimal dose that will be used in the Phase 3b part of this clinical trial....

Enrolling
Primary Membranous Nephropathy
Drug: SNP-ACTH (1-39) Gel
Drug: Rituximab

This is a parallel group, Phase 2, randomized, double-blind, placebo controlled, 5-arm, international, multicenter, 12-week proof of concept, dose fi...

Enrolling
Rheumatoid Arthritis
Drug: SAR441566
Drug: Placebo

This parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of obinutuzumab versus placebo in participants with...

Active, not recruiting
Systemic Lupus Erythematosus
Drug: Methylprednisolone
Drug: Acetaminophen/Paracetamol
Locations recently updated

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of RO7434656, a novel Antisense Oligonucleotide (ASO) therapy in...

Enrolling
Primary IgA Nephropathy
Drug: RO7434656
Drug: Placebo

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm monotherapy study for treatment of...

Enrolling
Dermatitis Atopic
Drug: Placebo
Drug: Amlitelimab

The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to e...

Enrolling
Primary Membranous Nephropathy
Drug: Tacrolimus
Drug: Zanubrutinib

This study is open to adults with a type of kidney disease called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out...

Active, not recruiting
Kidney Disease, Chronic
Drug: BI 764198
Drug: Placebo

The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivek...

Enrolling
Acute Myocardial Infarction (AMI)
Cardiovascular Risk
Drug: Ziltivekimab
Drug: Placebo

The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA...

Active, not recruiting
Immunoglobulin A Nephropathy
IgA Nephropathy
Drug: Placebo
Drug: Atrasentan

The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular d...

Active, not recruiting
Immunoglobulin A Nephropathy
Alport Syndrome
Drug: Atrasentan

This is a multinational, randomized, placebo-controlled, parallel treatment, Phase 2, double-blind, 2 arm study evaluating the efficacy and safety of...

Enrolling
Systemic Lupus Erythematosus
Drug: SAR441344 SC
Drug: Placebo SC

Trial sponsors

Novartis logo
Sanofi logo
C
Novo Nordisk logo
Pfizer logo
Roche logo
G
Vertex Pharmaceuticals logo
Amgen logo
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems